134 results about "Lung Inflammations" patented technology

The invention is applicable to the technical field of biology, and provides edible lactobacillus for relieving pulmonary fibrosis and application thereof, the edible lactobacillus for relieving pulmonary fibrosis provided by the embodiment of the invention is named as lactobacillus plantarum ZYHL3, is preserved in China Center for Type Culture Collection (CCTCC), has a preservation number of CCTCC No: M 2025127, has a preservation number of CCTCC No: M 2025127, and has a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, and a preservation number of CCTCC No: M 2025127. Lung inflammation and pulmonary fibrosis of mice can be remarkably relieved and disease prognosis can be improved by adjusting intestinal flora diversity and metabolic profiles, so that a new thought can be provided for preventing and treating pulmonary fibrosis diseases such as idiopathic pulmonary fibrosis and the like.

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

The invention discloses bifidobacterium longum subsp.infantis capable of relieving and preventing allergic rhinitis and application of the bifidobacterium longum subsp.infantis, and belongs to the technical field of microorganisms and the technical field of medicines. The bifidobacterium longum subsp. Infantis CCFM111 can relieve allergic reaction of allergic mice and relieve and prevent allergic diseases of perennial allergic rhinitis patients, and is specifically shown as follows: (1) weight loss and symptoms caused by allergy of the mice are relieved; lung inflammation infiltration is reduced; the OVA-sIgE level and the total IgE level of serum are reduced; the expression of a proinflammatory factor and an anti-inflammatory factor is regulated. (2) allergy symptoms and medication scores of patients are reduced; the asymptomatic day number proportion of the patient is increased; the serum dermatophagoides farinae and dermatophagoides farinae-sIgE level of patients is reduced; and the expression of cytokines in serum of a patient and nasal irrigation solution is regulated. Therefore, the bifidobacterium longum subsp. Infantis CCFM111 has a huge application prospect in preparation of products for preventing and / or treating allergic rhinitis.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a nauclea officinalis extract in preparation of a medicine for treating chronic obstructive pulmonary diseases. Experimental research shows that the nauclea officinalis extract is used for treating the chronic obstructive pulmonary disease, can inhibit lung inflammation of a patient suffering from the chronic obstructive pulmonary disease and improve the lung function and emphysema injury of the chronic obstructive pulmonary disease, can be used for preventing and treating the chronic obstructive pulmonary disease, and can be used for preventing and treating the chronic obstructive pulmonary disease. And a new strategy is provided for the development of medicines for treating chronic obstructive pulmonary diseases.

The invention discloses cubilose sialic acid glycan peptide capable of improving lung inflammation and application of the cubilose sialic acid glycan peptide. The ratio of fucose modified sugar chains in the cubilose sialic acid glycan peptide is 30-60%, the ratio of sialic acid modified sugar chains in the cubilose sialic acid glycan peptide is 20-40%, the core structure of the fucose type is (HexNAc) 3 (Man) 3 (Fuc) 1, the core structure of the sialic acid type is (HexNAc) 3 (Man) 3 (Gal) 1 (Fuc) 1 (NeuAc) 1, the neutral sugar dissolution rate of the cubilose sialic acid glycan peptide is high, and the glycopeptide shown in SEQ ID NO 2 has a good inflammation improving effect.

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.

The invention discloses an aza-four-membered ring connected pyrazolopyridine compound or pharmaceutically acceptable salt and application thereof, and the compound with the structure can be used as a novel high-selectivity PDE10A inhibitor for treating peripheral tissue diseases such as cardiac hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal function impairment and renal fibrosis. Lung inflammation and pulmonary fibrosis, immune regulation disorder and cancers (colon cancer, ovarian cancer and lung cancer). Through strategies in two aspects, the inhibition effect of the compound on a PDE10A high-selectivity inhibitor is reduced while the inhibition effect of the compound on a central nervous system is reduced. Firstly, in the aspect of molecular structure modification, the structure of the pyrazolopyridine compound connected with the aza-four-membered ring is optimized, for example, the polar surface area of molecules is increased by increasing the proportion of the number of N, O and S atoms in the molecular structure, and the fat solubility is reduced; and hydrophilic groups are introduced to increase water solubility and the like, so that the permeability of the compound to the blood brain barrier BBB is reduced. And 2, targeted drug delivery of lung tissues is realized by means of a pharmaceutical preparation.

The invention provides an application of alpha-melanocyte stimulant in treating asthma by inhibiting type II innate lymphocytes. An IL-7R-STAT pathway in activated lung ILC2 is inhibited through an alpha-MSH-MC5R axis, it is found that the neuroendocrine hormone alpha-MSH can target ILC2 to limit lung inflammation, and screening of new drugs for treating lung inflammation is facilitated.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid- and -metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

The invention discloses application of a cytisine type alkaloid and a derivative thereof in preparation of a medicine for preventing or treating respiratory syncytial virus infection, and relates to the technical field of respiratory syncytial virus prevention and treatment. The research finds that the natural product cytisine shows good anti-respiratory syncytial virus infection activity in vivo and in vitro, and finds that the cytisine can obviously relieve lung injury caused by virus infection and reduce lung inflammation; the invention provides an experimental basis for developing an efficient and safe drug for resisting respiratory syncytial virus (RSV) infection. As a natural product, the cytisine reduces the social burden caused by treatment of respiratory syncytial virus infection and reduces the treatment cost.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

The application discloses an FPR1 polypeptide blocker against lung inflammation and application thereof. The application provides a polypeptide shown in Sequence NO. 1, which can significantly improve lung tissue structure damage of a lung inflammation model mouse, reduce a proinflammatory factor level, reduce neutrophil infiltration, and show obvious anti-lung inflammation efficacy. Therefore, the polypeptide shown in Sequence NO. 1 has a prospect of development into an anti-lung inflammation drug.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

This invention discloses the application of 2,4-di-tert-butylphenol in the preparation of anti-human respiratory syncytial virus (RSV) drugs, belonging to the field of biomedical technology. 2,4-Di-tert-butylphenol exhibits good anti-RSV effects both in vitro and in vivo. In vitro, it can inhibit viral infection of cells, and in vivo, it can alleviate lung damage caused by viral infection and reduce lung inflammation. This invention provides experimental evidence for the development of highly effective and safe anti-RSV drugs and also offers more drug options for their development.

The application relates to kaempferol cerium nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The kaempferol cerium nanoparticles are prepared by performing coordination co-assembly on kaempferol and cerium ions in the presence of polyethylene glycol at a specific molar ratio, and the nanoparticles have uniform particle sizes and good dispersity. The nanoparticles have the anti-inflammatory activity of kaempferol and the ROS scavenging capacity of cerium ions, and show a significant synergistic effect in in-vivo and in-vitro experiments, can effectively reduce lung inflammation, inhibit oxidative stress, improve lung function, and have good biological safety, thereby providing a new drug candidate scheme for the treatment of ARDS.

Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 strain could modulate outcomes of chronic exposure to cigarette smoke in mice. In particular, they showed in mice chronically exposed to cigarette smoke that preventive and / or curative vaccination using BPZE1 could limit the lung inflammation and strongly contribute to the prevention of lung function decline. BPZE1 vaccination modulated pulmonary antigen presenting cells (macrophages and dendritic cells) to switch the immune response, by decreasing the IL-17 inflammatory pathway involved in the pathology of COPD itself, and by favouring a tolerogenic response (IL-10). Together, the data show that vaccination with BPZE1 of mice chronically exposed to cigarette smoke limits the development of chronic obstructive pulmonary disease outcomes and thus represents an interesting therapy.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The invention relates to the technical field of biological medicines, in particular to application of a CD20 inhibitor in treatment of chronic obstructive pulmonary diseases. The CD20 inhibitor can remarkably improve emphysema and small airway collagen deposition in chronic obstructive pulmonary diseases, inhibit expression of inflammatory factors IL-6 and TNF-alpha in lung tissue, reduce the concentration of chemotactic factors CXCL2 in bronchoalveolar lavage fluid and relieve lung inflammation, and the treatment effect is remarkable. Obviously, CD20 can become a potential clinical treatment target of chronic obstructive pulmonary disease.

The present invention provides an inhalable bionic nanomaterial for treating bacterial pneumonia of the lungs, and a preparation method and application thereof, belonging to the technical field of drug preparation. Mesoporous polydopamine nanoparticles A are prepared by a one-pot synthesis method using block polyether and 3,3',5,5'-tetramethylbenzidine as templates; levofloxacin is added to A, stirred and centrifuged, and freeze-dried to obtain nanoparticles B; RAW264.7 cells are resuspended after centrifugation, homogenized and centrifuged again to collect the supernatant, and the supernatant centrifugal precipitation is the prepared macrophage membrane C; the configured B solution and C are mixed, and a bionic nanomaterial D wrapped in a macrophage membrane coating is prepared by a direct extrusion method. The inhalable bionic nanomaterial prepared by the present invention can cross the complex lung barrier to target the inflammatory site to respond to the release of drugs, and can remove reactive oxygen to relieve lung inflammation, which is of great significance for the treatment of lung infection and has promotion and application value.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The invention discloses an exosome atomized preparation as well as a preparation method and application thereof, and belongs to the technical field of exosome technology and respiratory disease treatment. The problems that antibiotics and anti-inflammatory drugs adopted in the prior art have the defects of drug resistance, large side effects and the like in lung inflammation are solved. The exosome is derived from stem cells which are subjected to gp96 pretreatment and overexpress gp96 antigen information, the gp96 activates antigen presenting cells, the delivery efficiency of immunomodulatory factors (such as IL-10 and TGF-beta) carried by the exosome is enhanced, proinflammatory factors (such as TNF-alpha and IL-6) are inhibited, and in combination with the administration mode of an atomized preparation, through aerosol inhalation, the exosome can be used for preparing the immunomodulatory factor immunomodulatory agent. The exosome can directly reach a lung lesion area, so that the local drug concentration is improved, and the systemic side effects are reduced.

The invention discloses application of metformin to preparation of a medicine for preventing and / or treating bronchial lung dysplasia of a premature infant. It is found that the metformin can significantly reduce the death rate of bronchial pulmonary dysplasia (BPD) model young rats, reduce lung tissue macrophage and neutrophil infiltration, inhibit lung inflammation damage, prevent pulmonary alveolar septum widening and collagenous fiber deposition, reduce vascular exudation, promote lung tissue microangiogenesis and inhibit lung inflammation damage. And the survival rate and the BPD phenotype of the BPD young rats are obviously improved.

The invention discloses an application of an exosome carrying miR-486 in pulmonary interstitial fibrosis, and belongs to the technical field of biological medicines, and the exosome carrying miR-486 is an exosome carrying miR-486 from umbilical cord stem cells; according to the application disclosed by the invention, the umbilical cord stem cell-derived exosome carrying the miR-486 is used for treating the pulmonary interstitial fibrosis for the first time, and the action mechanism of the umbilical cord stem cell-derived exosome carrying the miR-486 is that the umbilical cord stem cell-derived exosome carrying the miR-486 regulates fibroblast MRC-5 cell differentiation and collagen deposition through targeting FGF9; the development process of pulmonary interstitial fibrosis is improved and delayed by improving lung inflammation of mice with pulmonary interstitial fibrosis caused by bleomycin, reducing collagenous fiber deposition, inflammatory response, ECM process and pulmonary vascular structure reconstruction, and a new way is provided for treatment of the disease.

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

The invention relates to a system for measuring a level of a subject's immune activity (10), the system comprising: - an exhaled air sensor (20), - a device for measuring exhaled air (30), - computation means (40) suitable for determining data relating to the air exhaled by the subject from the measurements carried out by the device (30), - a memory (60) suitable for storing the measurements performed by the device (30) and / or the data calculated by the means (40), and the subject's personal data, - a computation means (70) suitable for determining a level of the subject's immune activity on the basis of at least one item of exhaled air data, generated in real time by the means (40) and / or stored in the memory (60), - a communication and management interface (80) suitable for presenting said level of the subject's immune activity and / or sub-scores of immunological activity, inflammatory activity, digestive inflammation and / or pulmonary inflammation.

To provide a pharmaceutical composition for treating lung inflammation in a mammalian subject having a granulomatous pulmonary disease.SOLUTION: A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a GHRH antagonist.SELECTED DRAWING: None

The invention discloses application of arabinoxylan (AX) in preparation of a medicine for treating chronic obstructive pulmonary disease (COPD), and belongs to the technical field of medicines. The arabinoxylan (AX) can be used for preparing a medicine for treating the COPD (chronic obstructive pulmonary disease). Through a large number of researches, the inventor of the application finds that AX has a remarkable COPD treatment effect: lung inflammation in a mouse COPD model caused by haze can be reduced, the expression is that infiltration of mature T lymphocytes and macrophages in lung tissues is reduced, and the expression level of various proinflammatory factors including TGF-beta1 is reduced; the compound can weaken extracellular matrix deposition in the lung of a COPD mouse caused by haze, reduce the thickness of a tracheal wall, and reduce the expression of I-type collagen (collagen I) and a myofibroblast marker smooth muscle alpha2-actin (alpha-Sma); the emphysema degree of a COPD mouse induced by haze is also relieved; the AX also relieves abnormal changes of related protein levels of iron metabolism, mitochondrial metabolism, oxidative stress and glycometabolism in the lung tissue of the COPD mouse induced by haze. Therefore, AX can be used for preparing the medicine for treating COPD.